Idelalisib Completed Phase 2 Trials for Lymphoma, Hodgkins Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01393106Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma